Demant (WILLF): Premium Hearing Aid Pricing Firms as Device Costs Rise

Demant A/S (WILLF), the Danish hearing aid manufacturer, told its 2026 interim results call on August 12, 2026 that premium hearing aid pricing held through a heavy launch half. The global hearing aid market grew 4% in value and 3% in units in the first half of 2026, roughly a point of average selling price improvement, and the company's new flagship, Oticon Reveal, is priced above the outgoing Oticon Intent [1]. Demant is the only company with a direct disclosure on this, so what follows is a single case.

---

Why a more expensive device ends the launch discount

Hearing aids are sold in two pieces. Manufacturers build the device and the chip inside it, while the consumer usually goes to a hearing care chain or an independent audiologist for the hearing test, the fitting and the tuning, so the retail price covers both hardware and service. The industry convention is a new flagship every two or three years, launched at a concession on price to open distribution and hold share, with the previous generation discounted to clear inventory. After the United States allowed over-the-counter hearing aids, which consumers buy without a fitting professional, the general expectation was that premium prices would be ground down as well.

What changed this time is on the cost side. To run AI features continuously without giving up battery life or device size, manufacturers are packing more electronics and more compute onto a single chip, which lifts both the bill of materials and the R&D carried per device. Past a certain point, a launch discount has to come out of gross margin, and each additional unit sold absorbs the higher cost internally. Manufacturers working through their own cost math tend to land on the same choice, and the effect is confined to the premium lines where the cost increase is largest. Demant's management attributes the discipline to a cost of goods sold that technology keeps pushing up, and says several competitors show a similar trend and have been firmer on premium pricing [1]. The part about competitors is Demant's characterization of them, not their own disclosure.

---

Flagship pricing, market ASP and gross margin

The firmest reading is Demant's own pricing decision. Oticon Reveal integrates all functionality on a single power-efficient chip so that two AI systems can run continuously without limitation for the end user, and the device carries a net price increase over the prior flagship, Oticon Intent [1]. Across the market, the first half of 2026 delivered 4% value growth against 3% unit growth, and the roughly one point of difference is the average selling price moving up [1]. That half was the window in which manufacturers concentrated their launches, which under the old rule is when average prices are most likely to be pushed down.

The pricing discipline has reached realized profitability, though that figure needs a discount. Demant's first-half gross margin expanded one percentage point year over year to above 77%, ahead of management's own expectations. Management's order of drivers was favorable geography, channel and product mix in hearing aids lifting ASP, followed by the structurally higher gross margin of the acquired Kind hearing care retail business [1]. The second item comes from an acquired retail operation and cannot all be credited to wholesale price, and the market data is management's own reading as well. Whether competitors actually pulled their discounts at the same time cannot be checked here: the available earnings call transcript coverage spans the United States and Japan, which excludes Sonova, GN Store Nord, WS Audiology, Starkey, Amplifon and Cochlear, and a news search returned nothing usable [2][3].

---

Who absorbs the more expensive device

The pressure lands first on fitting and retail. A flagship entering the channel at a higher price raises the store's cost of goods before consumer price tolerance moves with it, which squeezes service pricing and promotional room in between. A manufacturer that integrates forward into retail and owns the chain converts this into an internal matter, with the store's margin consolidated onto its own statements alongside the higher device price and the channel cost.

Demant drew the boundary on this itself. It kept its full-year market growth assumption at a conservative 3% to 4%, below its own medium-term underlying growth expectation, and noted that the assumption already incorporates expected competitor launches in the second half; management also stated plainly that it cannot forecast competitors' product features or pricing strategies before those products reach the market, and that the cluster of premium launches could create renewed pricing pressure [1]. The metric to watch is whether the gap between full-year market value growth and unit growth stays positive. Once unit growth catches or passes value growth, average prices have been discounted back down.

---

Which companies this change could affect

• Sonova Holding AG (SOON.SW): one of the largest hearing aid manufacturers, concentrated in the same premium price band and facing the same more expensive chips and electronics, so how it prices its own second-half flagship determines whether Demant's increase holds; no disclosure of its own is available here.
• GN Store Nord A/S (GN.CO): the manufacturer exiting the hearing aid business, and where that asset ends up changes how many players remain in the premium band and how each of them carries its device costs; it makes no related disclosure in this material.
• Amplifon S.p.A. (AMP.MI): the leading hearing retail and fitting chain, now acquiring GN's hearing aid business and integrating upstream, which places it directly on the path where purchase costs rise before consumer prices follow; it likewise has no disclosure of its own here.

---

Sources

[1] Drillr · Demant A/S · 2026-08-12 · 2026 interim results call, full transcript (CFO outlook walk; Q&A with DNB Carnegie, Goldman Sachs and SEB)

"We have a growing cost of goods sold driven by technology, whether it's the production methodology or additional electronics or whatever it is, then you at some stage have to say that we have to install a stronger pricing discipline and also arguing for the benefit stronger for the end user, otherwise we have only done it for our own sake. and I think at least I can talk for Demand, but it seems like a number of competitors have similar trends and therefore have been more firm that margin dilution cannot happen and therefore have been more disciplined around pricing of the premium products, I would say in particular."

[2] Drillr · Sonova, GN Store Nord, WS Audiology, Starkey, Amplifon, Cochlear · 2026-08-13 · earnings call transcript coverage check (coverage spans the United States and Japan; no transcript returned for any of them)

[3] Drillr · hearing aid market pricing and average selling price · 2026-08-13 · news search (no relevant story returned)

This is only meant to surface industry changes and companies you may have overlooked - it is not a stock recommendation.